ADVERTISEMENT

Drug Combo Tames HER2-Positive Breast Cancer

New studies start to pinpoint the best strategy for treating HER2-positive breast cancer before surgery and lay the groundwork for future clinical trials. 

BY MELISSA WEBER
PUBLISHED THURSDAY, DECEMBER 9, 2010
Talk about this article with other patients, caregivers, and advocates in the Breast CURE discussion group.
Treatment for HER2-positive breast cancer turned a corner more than a decade ago with the approval of Herceptin (trastuzumab). More recently, another successful drug called Tykerb (lapatinib) hit the market. The question then became whether Herceptin, Tykerb or a combination of the two would be most effective in stifling the aggressive disease. Two studies presented at the San Antonio Breast Cancer Symposium offer some clues.

In the first study, nicknamed NeoALTTO, a combination of Tykerb, Herceptin and the chemotherapy drug Taxol (paclitaxel) outdid either targeted agent alone. Among 455 patients with HER2-positive breast cancer, giving the three-drug combo before surgery—known as neoadjuvant therapy—resulted in half of patients seeing cancer cells disappear completely in the breast at the time of surgery. The same pathological complete response was seen in only 30 percent of women receiving Herceptin alone, and 25 percent for Tykerb alone. Serious side effects were more common in the Tykerb-alone arm and included diarrhea, liver function problems, low white blood cell counts and rash. Although heart damage has been associated with HER2-targeted drugs, no patients experienced toxic effects to the heart at the time of surgery, researchers reported.

Similarly, investigators in the GeparQuinto study wanted to know which of the HER2-targeted drugs was more effective when given before surgery. In a head-to-head comparison, 620 women with HER2-positive disease received chemotherapy (epirubicin and cyclophosphamide followed by Taxotere [docetaxel]) plus either Herceptin or Tykerb. Like the NeoALTTO results, Herceptin edged out Tykerb when added to chemotherapy. No cancer cells were detected in the breast or lymph nodes at the time of surgery in 31 percent of patients on Herceptin compared with 22 percent receiving Tykerb. Serious cases of diarrhea and low white blood cell counts were seen in the Tykerb arm of the study.

Investigators of both studies will follow patients to see whether the absence of cancer cells at the time of surgery results in longer survival.

The HER2-targeted drug combo also works in combating advanced breast cancer. Last year in San Antonio, researchers reported that combining Herceptin and Tykerb helped women with heavily pretreated metastatic disease live approximately 4.5 months longer than Tykerb alone.

Excessive amounts of the HER2 protein cause cancer cells to grow more rapidly—a scenario associated with 20 to 25 percent of all breast cancers. Herceptin, approved for both early-stage and advanced cancers, targets the HER2 protein on the outside of cancer cells. Tykerb, currently approved only for advanced HER2-positive breast cancer, enters the cancer cell and blocks HER2—as well as growth signals from another protein called HER1—from inside the cell. Combining the two drugs could essentially knock out the cancer cell with a double blow.

While the studies were very encouraging, they’re not ready for use outside a clinical trial, said Eric Winer, MD, chief of the division of women’s cancers at Dana-Farber Cancer Institute in Boston. “We’ve been misled too often with early results. And while on the one hand we want to bring the best treatments to people as soon as possible, on the other hand, we have to have some greater assurance that they’re really having a meaningful effect.” 

Talk about this article with other patients, caregivers, and advocates in the Breast CURE discussion group.
ADVERTISEMENT
Related Articles
Telephone Intervention Helps Breast Cancer Survivors Set—and Meet—Lifestyle Goals
BY CHRISTINA IZZO
A new telephone-based intervention for breast cancer survivors is showing promise, and it involves them becoming more actively engaged in goal setting and problem solving with an eye toward accelerating their recovery by engaging in health-promoting activities such as exercise, stress management and healthy eating.
Diabetes May Predispose Women to More Advanced Breast Cancer
BY CHRISTINA IZZO
Breast cancer patients with diabetes were significantly more likely to be diagnosed with advanced-stage breast cancer than those without diabetes.
Crossing Tumor Types: BRCA Experience Points Way to New Diagnostic Paradigm
BY MAURIE MARKMAN, MD
It is now well recognized that the presence of a molecular abnormality shown to be actionable in one tumor type may be highly clinically relevant in other malignancies.
Is Immunotherapy Ready for Prime Time in Breast Cancer?
BY ANDREW D. SMITH
Elizabeth A. Mittendorf, associate professor of surgical oncology at The University of Texas MD Anderson Cancer Center, discusses the progress and potential of immunotherapy in breast cancer treatment.
Angelina Jolie, Knowledge Is Not Enough
Two years ago, Angelina Jolie Pitt told the world that she held the BRCA1 mutation.
Related Videos
Health Advocate Amy Byer Shainman Discusses Risk Management of Hereditary Cancers
When it comes to managing your risk of cancer, especially when dealing with a familial cancer risk, "what is right for one person, may not be right for another," says Amy Byer Shainman.
Research Updates on HER2-Positive Breast Cancer from the 2015 Miami Breast Cancer Conference
Debu Tripathy, editor-in-chief of CURE magazine, discusses updates from the Miami Breast Cancer Conference, including the changing landscape of HER2-positive breast cancer.
Medical Updates from the 32nd Annual Miami Breast Cancer Conference
The evolution of the treatment for hormone receptor-positive breast cancer was a hot topic for this year's Miami Breast Cancer Conference. Debu Tripathy, CURE's editor-in-chief and breast oncologist, reports from the meeting.
Joan Lunden Discusses the Physical and Emotional Effects of Breast Cancer Treatment
Journalist Joan Lunden shares her experience with breast cancer, side effects and working through treatment.
Journalist Joan Lunden Discusses Her Breast Cancer Diagnosis and Treatment
Roy Firestone interviews longtime journalist, author and television host Joan Lunden on her recent breast cancer diagnosis and treatment.
Recent Publications
  • photo
    photo
    photo
    photo
    photo
  • photo
    photo
    photo
    photo
    photo
ADVERTISEMENT
$auto_registration$